Registration certificates for BMKP expire by 31 December 2025 at the latest. Which pathway a cell or gene product takes now


Registration certificates for biomedical cell products (BMKP, complexes of cell lines with excipients) issued under the Federal Law «On Biomedical Cell Products» (hereinafter 180-FZ) remain valid until the end of their term, but not later than 31 December 2025. This was established by Federal Law No. 466-FZ of 4 August 2023 (hereinafter 466-FZ).
A high-technology medicinal product (VTLP in Russian law, ATMP in international practice; hereinafter ATMP) that is subject to registration under the law of the Eurasian Economic Union (EAEU) or under the Federal Law «On the Circulation of Medicines» (hereinafter 61-FZ) does not count as a BMKP. A product that a medical organization manufactures for a single patient and uses on its own premises is allowed on the basis of a permit issued by the Russian Ministry of Health.
The procedure for the circulation of such a product and the procedure for issuing the permit were approved by Resolutions of the Government of the Russian Federation No. 384 and No. 385 of 28 March 2024. Both resolutions are in force from 1 September 2024 to 1 September 2030.

Which product is an ATMP and which is an individual BMKP

Under 61-FZ, ATMPs are gene therapy medicinal products, medicinal products based on somatic cells and tissue-engineered products. Such products do not count as BMKP if they are subject to registration under the law of the EAEU or under 61-FZ (under 180-FZ).
Below, an individual BMKP means a BMKP intended to fulfill an individual medical prescription and manufactured specially for a particular patient directly in the medical organization where it is used. Manufacturers of BMKP are entitled to sell BMKP to other organizations. An individual BMKP is excluded from this right.
Therefore, a product manufactured for transfer to other organizations does not qualify for the single-patient access pathway. Access for such a product is governed by EAEU law and 61-FZ, if it meets the definition of an ATMP.

What has changed for BMKP registered under 180-FZ

Table 1. BMKP before and after 466-FZ

ParameterBeforeAfter
Term of the BMKP registration certificateA registration certificate is issued for five years and is renewed every five years upon confirmation of state registrationRegistration certificates issued under 180-FZ remain valid until the end of their term, but not later than 31 December 2025
Access of a product for a single patient180-FZ (as amended on 8 March 2022) contains no provision on such access. It was added by 466-FZ, in force since 1 April 2024Permit of the Russian Ministry of Health for production and use
Definition of BMKPThe definition of BMKP (180-FZ as amended on 8 March 2022) does not exclude transplantation objects and ATMPsTransplantation objects and ATMPs that are subject to registration under the law of the EAEU or under 61-FZ do not count as BMKP. For BMKP whose applications for state registration were submitted before 1 April 2024, the exclusion of such objects from the definition applies from 1 January 2026
Sale of an individual BMKP to other organizationsManufacturers of BMKP are entitled to sell BMKP to other manufacturers, scientific and educational organizations and organizations carrying out medical activity (180-FZ as amended on 8 March 2022)An individual BMKP is excluded from this right; sale is not permitted

Decision No. 78 of the Council of the Eurasian Economic Commission (EEC) on the Rules for Registration and Regulatory Assessment of Medicines for Medical Use (hereinafter Decision No. 78) sets transitional periods for registration certificates issued under the legislation of member states. The validity of national registration certificates of medicinal products is extended if, by 31 December 2025, an application for dossier alignment with EAEU law, or for changes to the dossier concerning the indication of states of recognition (member states that review the assessment report), has been submitted to the reference state (the member state that prepares the assessment report on the product), and the procedure has not been completed by that date.
The validity of the registration certificate is extended for the period of the procedure, but for not more than 3 years in each declared member state from the date the application was submitted to the reference state. It is also extended for the period of the procedure in the state of recognition, but for not more than 2 years from the date the application was submitted to that state. The application to the state of recognition is submitted no later than three years after the date of submission to the reference state. If the procedure in the reference state is completed before 31 December 2025, the validity of the registration certificate in the declared states of recognition is extended for the period of the procedure, but for not more than 2 years starting from 31 December 2025.
These transitional periods concern registration certificates of medicinal products issued under the legislation of member states. Registration certificates for BMKP are not named in them.

Access route for ATMPs under EAEU law

Registration of medicines in the EAEU is governed by the Rules for Registration and Regulatory Assessment approved by Decision No. 78. Fees for the procedures provided for by these Rules are approved by the member states.
In the cases and in the manner provided for by member state legislation, the Rules permit the provision to patients and the use of unregistered medicinal products. These include ATMPs that are manufactured on a non-standardized (non-routine) basis and used in the territory of the same member state in a treatment and prevention institution to fulfill an individual medical prescription for a medicinal product manufactured specially for a particular patient. Manufacture of such ATMPs is permitted by the authorized body of the member state. Member states must ensure the equivalence of the requirements for the traceability of batches and lots of medicinal products established by member state legislation and of the requirements for pharmacovigilance under the acts of the Union bodies.
Requirements for the quality, non-clinical and clinical aspects of developing products based on human somatic cells are set out in the Rules for Conducting Studies of Biological Medicines of the EAEU approved by Decision of the EEC Council No. 89 (hereinafter Decision No. 89). A separate section of these Rules covers products containing genetically modified cells. Both sections are analyzed in the article Gene and cell therapy in the EAEU. How to choose the right regulatory pathway, Chapters 31-32 of Decision No. 89.

How release into circulation differs for patient-derived ATMPs and other ATMPs

The requirements for releasing a batch into circulation differ for two groups of ATMPs. The first group is ATMPs obtained from the biological material of a specific person and intended for use in that same person (hereinafter patient-derived ATMPs). The second group is all other ATMPs.

Table 2. Release into circulation of patient-derived ATMPs and other ATMPs

RequirementPatient-derived ATMPsOther ATMPs
Test protocol at first release into circulationA test protocol for the first batches or lots of a product manufactured for the first time or imported into Russia for the first time is not required. A protocol of tests conducted using remote interaction tools is not submittedFor one batch or one lot of a product manufactured for the first time or imported into Russia for the first time, a protocol of tests conducted using remote interaction tools is submitted within the first three years after the product is released into civil circulation. The exemption that 61-FZ establishes for patient-derived ATMPs does not apply to this group
Annual test protocolMay be submitted once every three years, provided the product is released into civil circulationA test protocol for a product that entered civil circulation in the previous calendar year is submitted annually, no later than 1 April, for one batch of a trade name, taking into account the dosage form of one strength

Tests conducted using remote interaction tools (remote tests) for one batch or one lot of other ATMPs are also provided for by the Rules for Conducting Tests approved by Resolution of the Government of the Russian Federation No. 815 (hereinafter Resolution No. 815). The exemption for patient-derived ATMPs is repeated in these Rules.
The manufacturer or the organization that imports the ATMP is entitled, instead of the annual protocol, to submit information on a conclusion that the manufacturer complies with the requirements of the Good Manufacturing Practice (GMP) rules, or on a certificate that the production complies with the requirements of the EAEU GMP rules. The certificate is issued by the authorized body of an EAEU member state. The information states the date and registration number of the document. It is submitted for the site where the finished dosage form is manufactured and batch-release quality control is carried out. This right does not depend on which group the product belongs to (under 61-FZ).

Import and identification means for both groups of ATMPs

Registered original ATMPs may be imported into and circulated in Russia in packaging intended for circulation in foreign states, within 12 months after the date of registration in Russia, subject to the specific features established by the Government of the Russian Federation. The imported product must comply with the requirements established at registration, except for the requirements for primary and secondary packaging, and the secondary packaging must carry a self-adhesive label with information in Russian.
The provisions of 61-FZ under which the manufacturer’s quality document and confirmation that the product complies with the requirements established at registration must be submitted before each batch or lot is released into circulation do not apply to such products. Nor does the provision of 61-FZ on decisions based on the results of state control, including the withdrawal of a batch or lot from circulation and the transfer of a medicine to batch-by-batch selective quality control.
Identification means are not applied to ATMPs that are manufactured in small batches, consist of one or several doses, are intended for a specific patient and have a shelf life of up to 90 calendar days and/or a storage and transportation temperature of minus 60 °C or lower (under 61-FZ). The text of the provision does not name derivation from a patient’s material as a separate ground, so the product is checked against all the listed criteria.

Permit for an individual BMKP

The permit is issued by the Russian Ministry of Health to a medical organization. It remains valid indefinitely, subject to confirmation every 5 years from the date of grant or the last confirmation. The day the entry is made in the register of permits is considered the day of grant. For confirmation, the medical organization submits an application no earlier than 120 working days before the confirmation deadline. These provisions are contained in the Rules for the Grant, Confirmation and Cancellation of a Permit approved by Resolution of the Government of the Russian Federation No. 385 (hereinafter Resolution No. 385).
Production and use of an individual BMKP are allowed in a medical organization that complies with the requirements of the Rules for Circulation approved by Resolution of the Government of the Russian Federation No. 384 (hereinafter Resolution No. 384) and holds a permit. Under Resolution No. 384, the medical organization must hold a license for the production of BMKP and have an intensive care and resuscitation department (ward). If there is no license for the production of BMKP when the application is submitted, the Russian Ministry of Health takes its decision after receiving the review conclusions, provided that the register of licenses contains an entry on the license.
The application is submitted in electronic form through the Unified Portal of State and Municipal Services.
Copies of the following documents and information are attached to the application:
specification for the individual BMKP;
draft normative documentation;
draft mock-ups of the primary and secondary packaging;
report on the non-clinical study;
draft production regulations;
patient information sheet;
draft instructions for use;
documents confirming that an intensive care and resuscitation department (ward) exists;
information on the results of earlier scientific studies of the clinical use of this or a similar product (if available).

The Russian Ministry of Health decides to grant or refuse the permit on the basis of two reviews. The ethics council conducts the ethical review within up to 30 working days from the day it receives the Ministry’s assignment to conduct it. The applicant concludes a service contract with the expert institution within up to 5 working days from the day of applying to that institution. The expert institution conducts the biomedical review within up to 42 working days from the day the contract is concluded. If the Ministry has sent the applicant a request for documents and information, the biomedical review period is up to 50 working days from the day the contract is concluded. The applicant submits a response to such a request within up to 50 working days from the day of receiving it.
The Russian Ministry of Health refuses the permit in particular if the ethics council has found the production and use of the product ethically unjustified, the expert institution has found them impossible, or the applicant has no intensive care and resuscitation department (ward) or license for the production of BMKP.
No fee is charged for granting, confirming or cancelling a permit or for making changes to the register of permits. Resolution No. 385 and Resolution No. 384 contain no provisions on the cost of the expert institution’s services.
A batch of an individual BMKP is manufactured on the written request of the patient’s attending physician, on the basis of a decision of the medical commission of the medical organization. The information listed in Resolution No. 384 is marked on the primary and secondary packaging and on the transport container. The product is used in a day hospital or in an inpatient setting if the medical commission has decided to prescribe it to a specific patient. The medical organization sends the Federal Service for Surveillance in Healthcare (Roszdravnadzor) information on each instance of use.

Comparison of the two access pathways

Table 3. ATMPs under EAEU law and individual BMKP

ParameterATMPs under EAEU lawIndividual BMKP
Legal basis61-FZ, Decisions of the EEC Council No. 78 and No. 89180-FZ, Resolution No. 384, Resolution No. 385
Basis of accessRegistration of the medicinal product under the Rules for Registration and Regulatory AssessmentPermit of the Russian Ministry of Health issued to a medical organization
Fee for accessFees are approved by the member statesNot charged
Sale to other organizationsThe provisions of 180-FZ on the sale of BMKP do not apply, because an ATMP that is subject to registration under the law of the EAEU or under 61-FZ does not count as a BMKPNot permitted
Release of a batch into circulationProtocol of remote tests of one batch or lot (except for patient-derived ATMPs); annual protocol (for patient-derived ATMPs, once every three years is permitted) or information on GMPRequest of the attending physician and decision of the medical commission
Identification meansNot applied if the product meets the entire set of criteria established by 61-FZInformation applied to the packaging and transport container according to the list in Resolution No. 384

What to do

Classify the product in writing. Determine under 61-FZ whether the product is a gene therapy product, a product based on somatic cells or a tissue-engineered product. If the product will be transferred to other organizations, the single-patient access pathway does not apply to it. If in doubt, send a written inquiry to the Russian Ministry of Health on whether the product is an ATMP or a BMKP.
Compile a list of earlier registration certificates and applications under 180-FZ. Include all BMKP registration certificates issued under 180-FZ: their validity is limited to 31 December 2025. Add applications for state registration of BMKP submitted before 1 April 2024. For each item, request the status of the registration certificate or application from the Russian Ministry of Health in writing and decide whether to apply for registration of the product as an ATMP.
Prepare the ATMP dossier and decide whether GMP information is needed. Assemble the dossier under the Rules for Registration and Regulatory Assessment, taking into account the requirements of Decision No. 89 for products based on somatic cells and for products containing genetically modified cells. If you want to submit GMP information instead of the annual test protocol, obtain a conclusion that the manufacturer complies with GMP requirements or an EAEU GMP certificate for the site where the finished dosage form is manufactured and batch-release quality control is carried out.
Plan the release of a batch, imports and identification means. Determine which group the ATMP belongs to: patient-derived ATMPs or other ATMPs. For other ATMPs, provide for a protocol of remote tests of one batch or lot; for patient-derived ATMPs this protocol is not submitted. When importing an original ATMP in packaging intended for foreign states, prepare a self-adhesive label in Russian, stay within 12 months from the date of registration and check the specific features established by the Government of the Russian Federation. Check the product against all the criteria for exemption from identification means.
Submit a permit application if you are a medical organization. Check that you hold a license for the production of BMKP and have an intensive care and resuscitation department (ward). Submit the application through the Unified Portal of State and Municipal Services and allow 30 working days for the ethical review and 42 working days for the biomedical review. Mark 1 September 2030 in your plan. Both resolutions are in force until that date.


Regulatory framework:

1. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended 4 August 2026, applicable from 1 September 2026)
2. Federal Law No. 180-FZ of 23 June 2016 «On Biomedical Cell Products» (as amended 4 August 2023)
3. Federal Law No. 180-FZ of 23 June 2016 «On Biomedical Cell Products» (version of 8 March 2022, in force until 31 March 2024; for the «Before» rows)
4. Federal Law No. 466-FZ of 4 August 2023 «On Amendments to Article 4 of the Federal Law ‘On the Circulation of Medicines’ and the Federal Law ‘On Biomedical Cell Products’»
5. Resolution of the Government of the Russian Federation No. 384 of 28 March 2024 «On Approval of the Rules for the Circulation of Biomedical Cell Products Intended for Fulfilling an Individual Medical Prescription for a Biomedical Cell Product Specially Manufactured for a Particular Patient Directly in the Medical Organization Where That Biomedical Cell Product Is Used»
6. Resolution of the Government of the Russian Federation No. 385 of 28 March 2024 «On Approval of the Rules for the Grant, Confirmation and Cancellation of a Permit for the Production and Use of Biomedical Cell Products Intended for Fulfilling an Individual Medical Prescription»
7. Resolution of the Government of the Russian Federation No. 815 of 31 May 2025 «On the Procedure for Releasing Medicines for Medical Use into Civil Circulation»
8. Decision of the Council of the Eurasian Economic Commission No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Assessment of Medicines for Medical Use» (as amended 26 November 2025)
9. Decision of the Council of the Eurasian Economic Commission No. 89 of 3 November 2016 «On Approval of the Rules for Conducting Studies of Biological Medicines of the Eurasian Economic Union» (as amended 22 January 2025)

This page in Russian→